.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Metastasis remains the leading cause of cancer-related mortality worldwide. Even after modern treatment, dormant tumor cells (DTCs) often persist at distant sites in a quiescent state. These cells stop dividing but remain viable for years. Consequently, they frequently cause late recurrence by evading common therapies. Furthermore, they interact with the surrounding microenvironment to stay hidden. Understanding these mechanisms is essential for improving clinical outcomes in oncology. Researchers are now focusing on the complex relationship between these cells and the immune system.
Research suggests that dormant cells evade the immune system through several complex pathways. Specifically, these cells often downregulate MHC class I molecules. This change makes them invisible to cytotoxic T lymphocytes. Moreover, the scarcity of these cells makes physical contact with immune cells very rare. This phenomenon creates a significant barrier to effective immune-mediated clearance. Additionally, the stromal and vascular components of the niche protect these cells from detection. For instance, certain macrophages can promote dormancy or trigger eventual reactivation. Therefore, the tumor microenvironment serves as a shield against constant immune surveillance. Scientific advances now focus on disrupting this equilibrium. As a result, new immunotherapies aim to eliminate the reservoir of hidden cells. Targeting the niche might prevent the awakening of metastatic cells in the future. Clinicians must consider these hidden threats when planning long-term follow-up care.
Chemotherapy typically targets actively dividing cells. Since these cells remain in a quiescent or resting state, they do not respond to treatments aimed at rapid proliferation.
The microenvironment provides protective niches that regulate immune tolerance. It also physically separates tumor cells from immune players, which significantly reduces the likelihood of detection.
Recent studies suggest that T-cell-based vaccinations or CAR T-cell therapies could overcome the scarcity of cell interactions. These methods might help the immune system identify and kill hidden reservoirs.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Always seek the advice of a qualified physician or other health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Tiwary K et al. Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance. Mol Oncol. 2026 Apr 17. doi: 10.1002/1878-0261.70259. PMID: 41994877.
Goddard ET et al. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell. 2024;42(1):119-134. doi: 10.1016/j.ccell.2023.12.011.
Adam-Artigues A, et al. Immune evasion by dormant disseminated cancer cells: A Fermi paradox? Cancer Cell. 2024;42(1):13-15. doi: 10.1016/j.ccell.2023.12.017.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A review of how dormant tumor cells (DTCs) hide in the microenvironment and evade immune surveillance, leading to late cancer recurrence and survival....
4 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
